[go: up one dir, main page]

UY29274A1 - Composicion farmaceutica para tratar la hipertension, que comprende telmisartano e hidroclorotiazida - Google Patents

Composicion farmaceutica para tratar la hipertension, que comprende telmisartano e hidroclorotiazida

Info

Publication number
UY29274A1
UY29274A1 UY29274A UY29274A UY29274A1 UY 29274 A1 UY29274 A1 UY 29274A1 UY 29274 A UY29274 A UY 29274A UY 29274 A UY29274 A UY 29274A UY 29274 A1 UY29274 A1 UY 29274A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutical composition
telmisartane
hydroclorotiazida
treat hypertension
hydrochlorothiazide
Prior art date
Application number
UY29274A
Other languages
English (en)
Inventor
Peter Bohm
Axel Riedel
Helmut E Schumacher
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35589356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY29274(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY29274A1 publication Critical patent/UY29274A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Una composición farmacéutica que comprende aproximadamente 80 mg de telmisartano y aproximadamente 25 mg de hidroclorotiazida, o aproximadamente 160 mg de telmisartano y aproximadamente 50mg de hidroclorotiazida, para el tratamiento de la hipertensión en pacientes con una reducción de la tensión arterial insuficiente tras un tratamiento con un antagonista del receptor de angiotensina II, o una composición farmacéutica de un antagonista del receptor de angiotensina II y una dosis baja de hidroclorotiazida.
UY29274A 2004-12-17 2005-12-20 Composicion farmaceutica para tratar la hipertension, que comprende telmisartano e hidroclorotiazida UY29274A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63706204P 2004-12-17 2004-12-17

Publications (1)

Publication Number Publication Date
UY29274A1 true UY29274A1 (es) 2006-07-31

Family

ID=35589356

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29274A UY29274A1 (es) 2004-12-17 2005-12-20 Composicion farmaceutica para tratar la hipertension, que comprende telmisartano e hidroclorotiazida

Country Status (15)

Country Link
EP (1) EP1827424A1 (es)
JP (1) JP2008524136A (es)
KR (1) KR20070097511A (es)
CN (1) CN101080225A (es)
AR (1) AR052052A1 (es)
AU (1) AU2005315855A1 (es)
BR (1) BRPI0519656A2 (es)
CA (1) CA2589493A1 (es)
EA (1) EA200701159A1 (es)
IL (1) IL183944A0 (es)
NO (1) NO20072325L (es)
PE (1) PE20060768A1 (es)
TW (1) TW200637546A (es)
UY (1) UY29274A1 (es)
WO (1) WO2006063737A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US8637078B2 (en) * 2005-11-24 2014-01-28 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic
EP1970053A1 (en) * 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
US9072670B2 (en) * 2007-10-19 2015-07-07 Otsuka Pharmaceutical Co., Ltd. Matrix-type pharmaceutical solid preparation
EP2203158A4 (en) 2007-10-30 2012-12-26 Reddys Lab Ltd Dr PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE
EP2252273B1 (en) 2008-03-19 2016-12-28 ratiopharm GmbH Solid pharmaceutical composition comprising a non-peptide angiotensin ii receptor antagonist and a diuretic
MX2011001150A (es) 2008-07-31 2011-03-29 Takeda Pharmaceutical Composicion farmaceutica solida.
GB0822170D0 (en) * 2008-12-04 2009-01-14 Arrow Int Ltd Telmisartan with diuretic formulations
WO2010146187A2 (en) 2009-06-19 2010-12-23 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of telmisartan
WO2011002425A2 (en) * 2009-07-02 2011-01-06 Bilgig Mahmut Pharmaceutical composition increasing solubility and stability
WO2011002423A2 (en) * 2009-07-02 2011-01-06 Mahmut Bilgic Solubility enhancing pharmaceutical composition
TR200906506A2 (tr) 2009-08-24 2011-03-21 Bi̇lgi̇ç Mahmut Telmisartan içeren katı dozaj formları.
WO2011161123A2 (en) 2010-06-21 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Multilayer pharmaceutical tablet comprising telmisartan and a diuretic
WO2014119767A1 (ja) * 2013-01-31 2014-08-07 沢井製薬株式会社 テルミサルタンとヒドロクロロチアジドとを含有する多層錠剤
JP6422868B2 (ja) 2013-07-23 2018-11-14 第一三共株式会社 高血圧症の予防又は治療のための医薬
CN106562973A (zh) * 2016-11-06 2017-04-19 成都先先先生物科技有限公司 一种抗高血压药物复方制剂
CN107501192A (zh) * 2017-08-15 2017-12-22 中国科学院上海药物研究所 替米沙坦与氢氯噻嗪的共晶
CN108653227A (zh) * 2018-08-09 2018-10-16 湖北舒邦药业有限公司 一种替米沙坦氢氯噻嗪片及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4229085C2 (de) * 1992-09-01 1996-07-11 Boehringer Mannheim Gmbh Längliche, teilbare Tablette
WO2003059327A1 (en) * 2002-01-16 2003-07-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof

Also Published As

Publication number Publication date
AU2005315855A1 (en) 2006-06-22
JP2008524136A (ja) 2008-07-10
NO20072325L (no) 2007-07-06
EA200701159A1 (ru) 2007-12-28
CA2589493A1 (en) 2006-06-22
EP1827424A1 (en) 2007-09-05
WO2006063737A1 (en) 2006-06-22
KR20070097511A (ko) 2007-10-04
TW200637546A (en) 2006-11-01
PE20060768A1 (es) 2006-09-29
IL183944A0 (en) 2007-10-31
CN101080225A (zh) 2007-11-28
BRPI0519656A2 (pt) 2009-03-03
AR052052A1 (es) 2007-02-28

Similar Documents

Publication Publication Date Title
UY29274A1 (es) Composicion farmaceutica para tratar la hipertension, que comprende telmisartano e hidroclorotiazida
AR068185A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
ECSP099501A (es) Formulaciones de dosis unitaria y métodos para el tratamiento de la trombosis con un inhibidor oral del factor xa
UY32177A (es) Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
PA8635501A1 (es) Uso de un anticuerpo para el tratamiento del lupus
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
ECSP045430A (es) Terapia de combinación para el tratamiento de cancer
CO6150188A2 (es) Uso de teencteplasa para tratar un ictus isquemico agudo
CO6361942A2 (es) Terapia de combinacion con epoxicetonas peptidicas
CR11724A (es) Agente para tratar enfermedades
AR060306A1 (es) Terapia de combinacion de anticuerpos contra ctla4
AR033418A1 (es) Preparado farmaceutico mucoadhesivo desintegrable para la administracion de sustancia activa en medicina veterinaria y humana
AR054909A1 (es) Modulacion de los receptores activados por el proliferador de peroxisomas
CL2011000625A1 (es) Preparación sólida que comprende 2-etoxi-1-((2'-(5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil-4-il)metil)-1h-bencimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metilo, un agente regulador de ph y un compuesto antagonista de calcio; y metodos para utilizar y mejorar disolucion del compuesto en la preparacion solida.
AR051968A1 (es) Metodos y composiciones que utilizan inhibidores de jnk para el tratamiento y manejo de la lesion del sistema nervioso central
MX2009011900A (es) Curacion de herida diabetica.
ECSP078014A (es) Regimen de dosificacion para prasugrel
AR045783A1 (es) Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
AR048370A1 (es) Composicion para mejorar funciones cognitivas y la memoria
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
CR9200A (es) Uso de un agonista 5-ht6 para el tratamiento y la prevencion de trastornos neurodegenerativos
PE20091885A1 (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona
CL2008003558A1 (es) Composicion farmaceutica que comprende valrubicina y sulfoxido de dimetilo en forma de dosis intravesical, util para tratar cancer a la vejiga.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20161005